Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

253
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
253
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

194
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
194
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

159
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

138
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
138
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trastuzumab deruxtecan adverse drug reactions reported to the UK's Medicines and Healthcare products Regulatory Agency via the Yellow Card Reporting System.

ESMO open·2025
Same author

Real-time transrectal ultrasonographic measurement of the fetal eye (vitreous body) to predict parturition in bucking horse mares.

Journal of equine veterinary science·2025
Same author

Factors affecting pregnancy rates in mares bred with cryopreserved semen.

Journal of equine veterinary science·2024
Same author

Safeguard stewards of biodiversity knowledge-Response.

Science (New York, N.Y.)·2024
Same author

Recording of suspected adverse drug reaction reporting in veterinary free-text clinical narratives.

The Journal of small animal practice·2024
Same author

The global distribution of plants used by humans.

Science (New York, N.Y.)·2024

Related Experiment Video

Updated: May 5, 2026

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
02:47

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

2.2K

Cardiovascular pharmacogenomics: expectations and practical benefits.

R M Turner1, M Pirmohamed1

  • 11] The Wolfson Centre for Personalised Medicine, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK [2] Clinical Pharmacology, The Royal Liverpool University Hospital, Liverpool, UK.

Clinical Pharmacology and Therapeutics
|December 11, 2013
PubMed
Summary

Pharmacogenomics aims to personalize cardiovascular medicine using genetic information. However, clinical application faces significant barriers, with ongoing research into genetic associations with drug responses and risks.

More Related Videos

Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations
08:21

Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations

Published on: July 21, 2023

2.0K
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

7.9K

Related Experiment Videos

Last Updated: May 5, 2026

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
02:47

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

2.2K
Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations
08:21

Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations

Published on: July 21, 2023

2.0K
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

7.9K

Area of Science:

  • Cardiovascular Medicine
  • Pharmacogenomics
  • Genetics

Background:

  • Cardiovascular diseases are a major global health burden.
  • Pharmacogenomics offers personalized medicine by linking genetic variations to drug responses.
  • Current clinical practice lacks widespread cardiovascular pharmacogenomic applications due to various barriers.

Purpose of the Study:

  • To review the current state of cardiovascular pharmacogenomics.
  • To identify genetic associations with cardiovascular drug efficacy and adverse events.
  • To discuss barriers to clinical implementation and future directions.

Main Methods:

  • Literature review of pharmacogenomic studies in cardiovascular disease.
  • Analysis of genetic variants affecting drug metabolism and response (e.g., warfarin, clopidogrel, simvastatin).
  • Evaluation of evidence for clinical utility and implementation challenges.

Main Results:

  • Specific gene variants (VKORC1, CYP2C9, CYP4F2, CYP2C19, SLCO1B1, ADRB1, ADRA2C) are associated with warfarin, clopidogrel, and simvastatin response/toxicity.
  • Controversy remains regarding the clinical utility of some genetic associations.
  • Genetic variants are linked to drug-induced torsades de pointes.

Conclusions:

  • While promising, cardiovascular pharmacogenomics faces significant implementation hurdles.
  • Further research is needed to overcome evidential, logistical, financial, and knowledge barriers.
  • Anticipated practical benefits require substantial work to be realized in clinical practice.